CTOs on the Move

Rare Cancer Research Foundation

www.rarecancer.org

 
The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.rarecancer.org
  • 112 S. Duke Street Suite 101
    Durham, NC USA 27701
  • Phone: 919.827.8373

Executives

Name Title Contact Details

Similar Companies

Cell Signaling Technology

Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerber-Net

Cerber-Net is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CTMG

CTMG is a Greenville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nightingale Health

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone. We`re a team of 60 members––a diverse bunch with interdisciplinary expertise in business, marketing, computational medicine, data science, healthcare, IT, design and more––who envisage a world that focuses on keeping people healthy rather than just treating illnesses. So, if you are looking to enable good tech that could make a real difference, Nightingale is the place to be

Spruce Biosciences

Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).